Karius has raised $354M across 3 funding rounds, plus 2 undated rounds.
Karius is a venture-backed life science startup, with financial backing from investors including Khosla Ventures, General Catalyst, and 5AM Ventures, supporting its work applying next-generation sequencing to infectious disease diagnostics.
3 funding rounds, the latest highlighted.
Karius was founded in 2014, United States.
No date is disclosed for this round.
Bloomberg Beta, DCVC, Founder Collective, General Catalyst, Lightspeed Venture Partners, Aaron Levie, Drew Houston, Marc Benioff, Shishir Mehrotra, Todd Warren. $5M raised.
Bloomberg Beta, Cota Capital, Founder Collective, General Catalyst, Highbury Group, Khosla Ventures, OrbiMed, Pear VC, Tencent Holdings, Wndrco LLC, and others. $59M raised, led by DCVC, Lightspeed Venture Partners.
No filing has been made.
3 dated rounds, newest first.
Khosla VenturesLEADSSoftBank Vision Fund 2LEAD
DCVCLEAD
Lightspeed Venture PartnersLEAD
General Catalyst55AM VenturesGGilde HealthcareHHBM Healthcare InvestmentsBBlue Water Life SciencesThe closest healthcare / diagnostics peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Karius is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
